Su­per­nus touts AD­HD Phase III da­ta, but re­sults ap­pear to fall short of ex­pec­ta­tions

CNS-fo­cused Su­per­nus Phar­ma­ceu­ti­cals $SUPN re­port­ed pos­i­tive da­ta from keen­ly watched twin stud­ies test­ing its non-stim­u­lant AD­HD drug in chil­dren on Thurs­day, but the re­sults sug­gest­ed the treat­ment does not have a leg up over an ex­ist­ing gener­ic drug on the mar­ket.

Shares of the Rockville, Mary­land based-com­pa­ny were down about 13% in ear­ly trad­ing.

Two dos­es of the drug SPN-812 were test­ed against a place­bo in each study —  100mg/200mg in study P301, and 200mg/400 mg in study P303.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.